Lung cancer gene type and the chance of spread to the brain
Original title: EGFR Mutation Subtype and Risk of Brain Metastases From Non-Small Cell Lung Cancer in the Osimertinib Era: EGFR Subtype and Brain Metastases in NSCLC.
How far along is this research?
- Lab cells
- Animals
- Review
- Tested in people
This was tested in people. That is the most reliable kind of research we share.
This looked at records of real patients, but it did not test a treatment.
The short version
With a newer lung cancer drug, two common gene types had a similar chance of spreading to the brain.
What was studied. Researchers looked back at the health records of 647 people with lung cancer. All had a change in a gene called EGFR, and none had cancer in the brain when first diagnosed.
What they found. On older pills, people with a gene change called L858R more often had cancer spread to the brain than people with the Exon 19 change. After 5 years, 46.2% of the L858R group had no brain spread, compared with 64.5% of the Exon 19 group. For 398 people on the newer drug osimertinib, the two groups did about the same, at 53.4% and 53.1%.
What this means, and what it doesn't
What it could mean: If you have this kind of lung cancer, the newer drug may even out the brain spread risk between these two gene types. This could be a good question to ask your cancer doctor.
What it doesn't mean: This study only looked back at past records. It did not test a new treatment. It does not prove that the newer drug stops cancer from spreading to the brain. It is not a cure.
Source: PubMed, September 15, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.